Table 2 Prevalence of HPV by Bethesda classification system

HR‡

Negative†

9

[31, 35, 39, 48, 49, 51, 52, 54, 57]

1451

15102

40.5% (26.4%-54.6%)

Benign

2

[51]

42

275

15.7% (9.3%-22.0%)

ASC-US

5

[31, 39, 48, 51, 53, 54]

136

350

40.5% (26.4%-54.6%)

LSIL

10

[31, 35, 39, 45, 48, 49, 51, 52, 54, 57]

928

1563

73.6% (55.3%-91.8%)

HSIL

8

[31, 35, 39, 45, 51, 54, 57, 78]

559

628

89.9% (84.8%-95.1%)

Cervical Cancer

2

[51, 54]

2

3

*

16

Negative

6

[35, 39–41, 48, 52]

473

6017

7.9% (4.9%-11.0%)

Benign

1

[39]

2

250

*

ASC-US

1

[48]

0

17

*

LSIL

7

[35, 39–41, 45, 48, 52]

506

1925

28.3% (15.1%-41.5%)

HSIL

7

[35, 39–41, 45, 48, 61]

516

1068

54.0% (45.6%-62.4%)

Cervical Cancer

3

[38, 43, 61]

81

172

48.8% (34.0%-63.6%)

18

Negative

5

[35, 39, 40, 42, 48]

156

4891

3.6% (1.6%-5.6%)

Benign

1

[39]

14

250

*

ASC-US

1

[48]

2

17

*

LSIL

6

[35, 39, 40, 42, 48, 52]

81

1312

5.8% (3.6%-7.9%)

HSIL

5

[35, 39, 40, 42, 48]

47

662

7.9% (3.8%-12.0%)

Cervical Cancer

4

[38, 42, 43, 80]

42

219

17.1% (6.4%-27.9%)

31

Negative

4

[35, 39, 40, 48]

33

4849

2.1% (0.1%-4.1%)

Benign

1

[39]

2

250

*

ASC-US

1

[48]

0

17

*

LSIL

5

[35, 39, 40, 48, 52]

76

1241

7.3% (2.7%-11.8%)

HSIL

4

[35, 39, 40, 48]

64

432

14.2% (4.0%-24.5%)

Cervical Cancer

3

[38, 43, 61]

3

172

1.2% (0.0%-2.73%)

33

Negative

4

[35, 39, 40, 48]

38

4849

0.6% (0.0%-1.3%)

Benign

1

[39]

1

250

*

ASC-US

1

[48]

2

17

*

LSIL

4

[35, 39, 40, 48]

35

884

3.6% (1.2%-6.0%)

HSIL

4

[35, 39, 40, 48]

24

432

5.6% (3.5%-7.8%)

Cervical Cancer

3

[38, 43, 61]

4

172

2.1% (0.0%-4.2%)

35

Negative

4

[35, 39, 40, 48]

28

4849

0.5% (0.3%-0.8%)

Benign

1

[39]

1

250

*

ASC-US

1

[48]

0

17

*

LSIL

4

[35, 39, 40, 48]

31

884

3.1% (0.3%-6.0%)

HSIL

4

[35, 39, 40, 48]

8

432

1.8% (0.5%-3.0%)

Cervical Cancer

3

[38, 43, 61]

0

172

*

39

Negative

3

[39, 40, 48]

11

4770

0.8% (0.0%-2.0%)

Benign

1

[39]

0

250

*

ASC-US

1

[48]

1

17

*

LSIL

3

[39, 40, 48]

6

860

0.6% (0.0%-1.5%)

HSIL

3

[39, 40, 48]

2

374

*

Cervical Cancer

2

[38, 61]

1

96

*

45

Negative

3

[39, 40, 48]

31

4770

0.6% (0.4%-0.9%)

Benign

1

[39]

0

250

*

ASC-US

1

[48]

0

17

*

LSIL

3

[39, 40, 48]

9

860

1.1% (0.4%-1.7%)

HSIL

3

[39, 40, 48]

6

374

*

Cervical Cancer

2

[38, 61]

8

96

7.7% (2.4%-13.0%)

51

Negative

3

[39]

7

4470

*

Benign

1

[39]

0

250

*

ASC-US

1

[48]

1

17

*

LSIL

3

[39, 40, 48]

2

860

*

HSIL

3

[39, 40, 48]

3

374

*

Cervical Cancer

2

[38, 61]

0

96

*

52

Negative

4

[39, 40, 48, 52]

41

5530

1.4% (0.1%-2.7%)

Benign

1

[39]

0

250

*

ASC-US

1

[48]

1

17

*

LSIL

4

[39, 40, 48, 52]

50

1217

2.9% (0.8%-5.1%)

HSIL

3

[39, 40, 48]

9

374

2.4% (0.9%-4.0%)

Cervical Cancer

2

[38, 61]

3

96

2.6% (0.0%-7.1%)

56

Negative

3

[39, 40, 48]

74

4770

1.4% (0.8%-2.0%)

Benign

1

[39]

5

250

*

ASC-US

1

[48]

0

17

*

LSIL

3

[39, 40, 48]

52

860

5.8% (3.2%-8.3%)

HSIL

3

[39, 40, 48]

4

374

*

Cervical Cancer

2

[38, 61]

2

96

1.6% (0.0%-4.1%)

58

Negative

4

[35, 39, 40, 48]

37

4849

1.0% (0.3%-1.6%)

Benign

1

[39]

0

250

*

ASC-US

1

[48]

0

17

*

LSIL

4

[35, 39, 40, 48]

22

884

2.3% (1.3%-3.3%)

HSIL

4

[35, 39, 40, 48]

11

432

2.0% (0.0%-4.3%)

Cervical Cancer

2

[38, 61]

0

96

*

59

Negative

3

[39, 40, 48]

25

4770

0.5% (0.0%-1.1%)

Benign

1

[39]

2

250

*

ASC-US

1

[48]

1

17

*

LSIL

3

[39, 40, 48]

9

860

0.9% (0.3%-1.6%)

HSIL

3

[39, 40, 48]

9

374

2.1% (0.7%-3.6%)

Cervical Cancer

2

[38, 61]

0

96

*

68

Negative

3

[39, 40, 48]

5

4470

*

Benign

1

[39]

0

250

*

ASC-US

1

[48]

0

17

*

LSIL

3

[39, 40, 48]

1

860

*

HSIL

3

[39, 40, 48]

2

374

*

Cervical Cancer

2

[38, 61]

1

96

*